Accendra Health, Inc. · NYSE (us_market)
Healthcare · Medical Distribution · United States
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines including ostomy, wound care and negative pressure wound therapy, urology, incontinence, and other products and services. It serves patients and home health agencies. The company was formerly known as Owens & Minor, Inc. and changed its name to Accendra Health, Inc. in December 2025. Accendra Health, Inc. was founded in 1882 and is based in Glen Allen, Virginia.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-11-07$3.18 RISE2026-03-20$1.96 PEAK2026-05-11$3.89 185d | -38.4% 133d | Missed | Missed | — | — | +98.5% 52d | Missed |
DROP2025-09-05$5.62 RISE2026-01-06$1.91 PEAK2026-01-12$2.68 129d | -66.0% 123d | Missed | Missed | — | — | +40.3% 6d | Missed |
DROP2025-07-01$9.42 RISE2025-08-11$4.63 PEAK2025-08-15$5.68 45d | -50.8% 41d | Missed | Missed | — | — | +22.7% 4d | Missed |
DROP2025-01-27$15.07 RISE2025-06-02$6.35 PEAK2025-07-01$9.42 155d | -57.9% 126d | Missed | Missed | — | — | +48.3% 29d | Missed |
DROP2025-01-27$15.07 RISE2025-04-22$6.47 PEAK2025-07-01$9.42 155d | -57.1% 85d | Missed | Missed | — | — | +45.6% 70d | Missed |
DROP2025-01-27$15.07 RISE2025-02-21$6.22 PEAK2025-03-19$10.09 51d | -58.7% 25d | Missed | Missed | — | — | +62.2% 26d | Missed |
DROP2024-07-23$16.48 RISE2024-11-05$11.80 PEAK2025-01-27$15.07 188d | -28.4% 105d | Missed | Missed | — | — | +27.7% 83d | Missed |
DROP2024-03-27$27.95 RISE2024-07-05$12.59 PEAK2024-07-23$16.48 118d | -55.0% 100d | Missed | Missed | — | — | +30.9% 18d | Missed |
DROP2023-12-14$23.00 RISE2024-01-16$18.44 PEAK2024-03-27$27.95 104d | -19.8% 33d | Missed | Missed | — | — | +51.6% 71d | Missed |
DROP2023-08-09$20.36 RISE2023-10-27$13.87 PEAK2023-12-14$23.00 127d | -31.9% 79d | Missed | Missed | — | — | +65.8% 48d | Missed |
DROP2023-06-07$21.71 RISE2023-08-21$15.76 PEAK2023-11-07$19.74 153d | -27.4% 75d | Missed | Missed | — | — | +25.3% 78d | Missed |
DROP2023-02-02$22.48 RISE2023-05-04$13.55 PEAK2023-06-07$21.71 125d | -39.7% 91d | Missed | Missed | — | — | +60.2% 34d | Missed |
DROP2023-02-02$22.48 RISE2023-03-23$12.11 PEAK2023-06-07$21.71 125d | -46.1% 49d | Missed | Missed | — | — | +79.3% 76d | Missed |
DROP2022-08-12$35.57 RISE2022-12-20$19.04 PEAK2023-02-02$22.48 174d | -46.5% 130d | Missed | Missed | — | — | +18.1% 44d | Missed |
DROP2022-08-02$36.64 RISE2022-10-12$15.10 PEAK2022-12-08$21.51 128d | -58.8% 71d | Missed | Missed | — | — | +42.5% 57d | Missed |
1–15 / 26 1 / 2 | |||||||
Investors need to pay close attention to ACH stock based on the movements in the options market lately.
2026-05-14. The following slide deck was published by Accendra Health, Inc.
Accendra Health, Inc. (ACH) Shareholder/Analyst Call May 14, 2026 9:00 AM EDTCompany ParticipantsMark BeckHeath Galloway - Executive VP, General Counsel...
Presentation Operator MessageOperator Hello, and welcome to the Annual Meeting of Shareholders of Accendra Health Incorporated. Please note that today's meeting is being recorded. [Operator...
UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and raises the price target from $3 to $4.5.
Citigroup analyst Daniel Grosslight maintains Accendra Health (NYSE:ACH) with a Buy and raises the price target from $3.25 to $5.
Baird analyst Eric Coldwell maintains Accendra Health (NYSE:ACH) with a Outperform and raises the price target from $5 to $6.
Despite a challenging quarter marked by a revenue decline, Accendra Health Inc (ACH) focuses on debt reduction and growth in key categories like sleep therapy and home respiratory care.
The press release, along with the first quarter 2026 supplemental slides, which we will refer to throughout the call are posted in the Investor Relations section of our website. Please note that during the call, we will make forward-looking statements that reflect the current views of sundra Health about our business, financial performance and future events.
Accendra Health's multiyear turnaround: refinancing cuts debt ~$100M & boosts liquidity. Click for this ACH earnings update and a look at the stock's valuation.
Accendra Health, Inc. (NYSE:ACH) shares surged nearly 10% in premarket trading on Monday after the home-based healthcare company reported first-quarter 2026 earnings that came in ahead of analyst expectations.
Accendra Health, Inc. (ACH) Q1 2026 Earnings Call May 11, 2026 8:30 AM EDTCompany ParticipantsWill ParrishEdward Pesicka - President, CEO &...
Accendra Health (ACH) beat Q1 2026 EPS estimates and announced a $1.5B debt restructuring, sending shares up over 4% pre-market despite a revenue miss.
Will Parrish, Vice President | Strategy, Corporate Development, and Investor Relations 3 ...
Accendra Health (NYSE:ACH) affirms FY2026 sales outlook from $2.550 billion-$2.650 billion to $2.550 billion-$2.650 billion vs $2.590 billion estimate.
Presentation Operator MessageOperator Hello. Good morning, and thank you for standing by. Welcome to the Accendra Health's First Quarter 2026 Earnings Conference Call. Please be advised that
Accendra Health, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported sales was USD 627.78 million compared to USD 673.88 million a...
First Quarter 2026 Continuing Operations Supplemental Slides May 11, 2026 About Accendra Health Accendra...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ACH | -24.06% | +20.85% | +1.43% | -56.97% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -27.03% | +26.57% | +4.87% | -69.66% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| DEShaw | quant | 3.31M | $7.55M | 0.00% | Trimmed-6.9% | 2026-03-31 |
| StateStreet | passive | 1.63M | $3.72M | 0.00% | Added+1.8% | 2026-03-31 |
| TwoSigma | quant | 1.20M | $2.74M | 0.00% | Added+1.7% | 2026-03-31 |
| RenTech | quant | 317.9K | $724.84K | 0.00% | Trimmed-22.0% | 2026-03-31 |
| Citadel | multi-strat | 53.9K | $122.93K | 0.00% | Trimmed-93.2% | 2026-03-31 |
| FidelityFMR | fundamental | 24.5K | $55.86K | 0.00% | Added+98.1% | 2026-03-31 |
| TRowePrice | fundamental | 81.7K | $187 | 0.00% | Added+2.3% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-20 | Galloway Heath H | EVP,General Counsel & CorpSecy | F Tax withholding | 1,822 | $2.91 | −$5.3K |
| 2026-05-19 | Bernocchi Perry A | EVP, Chief Operating Officer | F Tax withholding | 7,908 | $3.04 | −$24.0K |
| 2026-05-19 | Galloway Heath H | EVP,General Counsel & CorpSecy | F Tax withholding | 966 | $3.04 | −$2.9K |
| 2026-05-19 | Pesicka Edward A | President & CEO | F Tax withholding | 17,692 | $3.04 | −$53.8K |
| 2026-05-19 | Leon Jonathan A | EVP & CFO | F Tax withholding | 1,770 | $3.04 | −$5.4K |
| 2026-05-18 | Beck Mark A | Director | A Grant / award | 31,191 | — | +$0 |
| 2026-05-18 | Bingham Gwendolyn M | Director | A Grant / award(deriv) | 31,191 | — | +$0 |
| 2026-05-18 | Gardner-Smith Kenneth | Director | A Grant / award | 31,191 | — | +$0 |
| 2026-05-18 | Klemash Stephen W | Director | A Grant / award | 31,191 | — | +$0 |
| 2026-05-18 | Kline Teresa L. | Director | A Grant / award | 31,191 | — | +$0 |
| 2026-03-24 | Galloway Heath H | EVP,General Counsel & CorpSecy | F Tax withholding | 9,347 | $2.03 | −$19.0K |
| 2026-03-24 | Bernocchi Perry A | EVP, Chief Operating Officer | F Tax withholding | 20,841 | $2.03 | −$42.3K |
| 2026-03-24 | Leon Jonathan A | EVP & CFO | F Tax withholding | 11,286 | $2.03 | −$22.9K |
| 2026-03-24 | Pesicka Edward A | President & CEO | F Tax withholding | 58,945 | $2.03 | −$119.7K |
| 2026-03-10 | Galloway Heath H | EVP,General Counsel & CorpSecy | A Grant / award | 61,437 | — | +$0 |
| 2026-03-10 | Leon Jonathan A | EVP & CFO | A Grant / award | 85,067 | — | +$0 |
| 2026-03-10 | Bernocchi Perry A | EVP, Chief Operating Officer | A Grant / award | 108,696 | — | +$0 |
| 2025-11-20 | Long Andrew G | EVP, CEO P&HS | G Gift | 47,908 | — | +$0 |
| 2025-09-24 | Leon Jonathan A | EVP & CFO | F Tax withholding | 4,265 | $5.40 | −$23.0K |
| 2025-08-14 | Coliseum Capital Management, LLC | 10% Owner | P Open-market purchase | 492,852 | $5.31 | +$2.62M |
| 2025-08-14 | Coliseum Capital Management, LLC | 10% Owner | P Open-market purchase | 325,000 | $5.46 | +$1.77M |
| 2025-08-14 | Coliseum Capital Management, LLC | 10% Owner | P Open-market purchase | 720,000 | $5.15 | +$3.71M |
| 2025-06-04 | Stone Jennifer A | EVP, CHRO | F Tax withholding | 5,764 | $6.35 | −$36.6K |
| 2025-05-20 | Galloway Heath H | EVP,General Counsel & CorpSecy | F Tax withholding | 1,768 | $7.38 | −$13.0K |
| 2025-05-16 | Bernocchi Perry A | EVP, CEO,. Patient Direct | F Tax withholding | 13,394 | $7.00 | −$93.8K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-10upcoming | -0.09 | — | — |
| 2026-05-11 | -0.10 | -0.04 | +59.31% |
| 2026-02-19 | -0.13 | -0.73 | -447.51% |
| 2025-10-30 | -0.07 | -1.94 | -2671.43% |
| 2025-08-11 | 0.28 | 0.26 | -5.73% |
| 2025-05-08 | -0.15 | -0.32 | -118.18% |
| 2025-02-28 | 0.52 | 0.55 | +5.68% |
| 2024-11-04 | 0.41 | 0.42 | +1.41% |
| 2024-08-02 | 0.33 | 0.36 | +7.58% |
| 2024-05-03 | 0.18 | 0.19 | +5.88% |
| 2024-02-20 | 0.66 | 0.69 | +4.02% |
| 2023-11-03 | 0.38 | 0.44 | +17.29% |
| 2023-08-04 | 0.18 | 0.18 | +1.07% |
| 2023-05-05 | -0.09 | 0.05 | +154.52% |
| 2023-02-28 | 0.40 | 0.28 | -30.20% |
| 2022-11-02 | 0.39 | 0.41 | +4.17% |